[Report] Drug Discovery Technologies TOC

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. Industry Overview II-1

Drug Discovery Outsourcing - A Necessity II-1
Leading Drug Discovery Service Providers II-1
Table 1: World Drug Discovery Outsourcing Market (2004): Percentage Breakdown of Outsourced Revenue by Top 10 Service Providers (includes corresponding Graph/Chart) II-2
Current & Future Analysis II-2
Analysis by Geographic Region II-2
Analysis by Technology Type II-3

2. Market Trends II-4

New Technologies Fire Up Drug Discovery Market II-4
Obesity Related Diseases Driving Drug Discovery Research II-4
Biochips Change Face of Drug Discovery II-4
Genomics and Proteomics Gaining Prominence II-4
Genomics Drives Bioinformatics Growth in Drug Discovery II-5
Market Scenario of Human Genome Sciences (HGS) II-5
International Initiatives Expand Proteomics II-5

3. Drug Discovery - An Overview II-6

Drug Discovery - Definition II-6
Drug Discovery Process II-6
Drug Discovery Technologies II-6
Bioanalytical Instruments II-7
Nuclear Magnetic Resonance II-7
Mass Spectroscopy II-7
Microplate Readers II-7
Chemotherapy II-7
High Throughput Screening II-7
Genomics II-8
Functional Genomics II-8
Structural Genomics II-8
Proteomics II-8
Classification of Proteomics II-8
Bioinformatics II-9
Categories of Bioinformatics II-9
Advantages of Bioinformatics in Drug Discovery II-9
Biochip II-9
Types of Biochips II-9
Pharmacogenomics II-10

4. Product Launches II-11

Sigma-Aldrich Introduces GenomePlex® II-11
Agilent Unveils Dual Mode Microarray Platform II-11
Molecular Devices Launches ImageXpressULTRAEII-11
Applied Biosystems Commercializes TaqMan® Influenza II-11
Agilent Launches Assay Kits for Lab-On-a-Chip Platform II-11
Affymetrix Unveils GeneChip® Microarrays II-11
Quantum Introduces Drug Discovery Software II-12
Invitrogen Launches StealthERNAi Human Kinase Collection II-12
PerkinElmer Unveils BioXPRESSIONEII-12
Affymetrix and ParAllele Jointly Introduce MegAlleleEAssays II-12
Agilent Launches HD-CGH Custom Microarrays II-12
Applied Biosystems and MDS Sciex Unveil TempoELC II-12
Beckman Coulter Presents Chemistry Analyzer for Clinical Testing II-13
Molecular Devices Launches ADME Assay Kits II-13
Applied Biosystems Unveils LS*LIMSESoftware II-13
Affymetrix Presents NimbleExpressEII-13
Agilent Releases Software for Pharma QC/QA II-13

5. Recent Industry Activity II-14

PerkinElmer Acquires Proteomics
Technology from Agilix II-14
BD Finishes Acquisition of GeneOhm II-14
Albany Acquires ComGenex in Hungary II-14
Agilent Acquires Yokogawa II-15
Cellomics and Evotec Sign a Patent License Agreement II-15
PerkinElmer Opens New Technology Center in Shanghai II-15
Affymetrix Acquires ParAllele II-15
Agilent Acquires Computational Biology II-16
MultiCell and Living Cell Enter into a Joint Venture II-16
Fujitsu and Ensemble Enter into Licensing Agreement II-16
Structural GenomiX Modifies Licensing Agreement with Lilly II-17
Provid Enters into Research Services Agreement with Palatin II-17
NascaCell Signs Co-marketing Agreement with DPI II-17
Evotec and P&G Sign Supply Agreement II-17
Invitrogen Signs Collaborative Agreement with NCDS II-17
HistoRx Enters into Collaboration with Eli Lilly II-18
Invitrogen and Applied Biosystems Forge Strategic Alliance II-18
UCB and ChemBridge Form Collaboration in Discovery Chemistry II-18
Pharmacopeia and CV Therapeutics Form Drug Discovery and Development Collaboration II-18
OriGene Enters into Collaboration with Cytomyx II-18
Discovery Partners Divests Discovery Systems Business to Nexus II-19
CRL Acquires River Valley Farms II-19
Agilent Acquires Silicon II-19
Medarex Acquires Ability Biomedical II-19
National Instruments Enters into Joint Venture Agreement with Agilent II-19
Amersham Enters into 3-Year Distribution Agreement with Guava II-20
ChemBridge Signs an Agreement with Merck & Co. II-20
Bristol-Myers Collaborates with MEDX II-20
Bayer Enters into Partnership with Physiomics II-20
Pharmacopeia Spins-Off Pharmacopeia Drug Discovery II-20
Abbott Enters into Collaboration with Caprion II-20
Vertex Divests Instrumentation Assets to Aurora II-21

6. Focus on Select Global Players II-22

Abbott Laboratories (US) II-22
Affymetrix Inc. (US) II-22
Agilent Technologies Inc. (US) II-22
Albany Molecular Research, Inc. (US) II-22
Amersham Biosciences (US) II-22
Applera Corporation (US) II-23
ArQule Inc. (US) II-23
AstraZeneca (UK) II-23
BD Biosciences (US) II-23
Bio-Rad Laboratories, Inc. (US) II-23
BioSciences Group (Japan) II-24
Caliper Life Sciences, Inc. (US) II-24
Capital GenomiX (US) II-24
Caprion Pharmaceuticals Inc. (Canada) II-24
Charles River Laboratories International, Inc. (US) II-24
ChemBridge Corporation (US) II-25
deCODE Genetics, Inc (Iceland) II-25
Discovery Partners International Inc. (US) II-25
Evotec AG (Germany) II-25
ICOS Corporation (US) II-25
Incyte Corporation (Formerly Incyte Genomics Inc.) (US) II-25
Inpharmatica (UK) II-25
Invitrogen Corporation (US) II-26
Medarex, Inc. (US) II-26
Merck & Co., Inc. (US) II-26
Millennium Pharmaceuticals, Inc. (US) II-26
National Center for Drug Screening (China) II-26
PerkinElmer, Inc. (US) II-26
Pharmacopeia Drug Discovery, Inc. (US) II-27
Proteome Systems (Australia) II-27
Quantum Pharmaceuticals (Russia) II-27
Shimadzu Corporation (Japan) II-27
Sigma-Aldrich (US) II-27
Tecan Group (Switzerland) II-27
Tripos, Inc. (US) II-28

7. Global Market Perspective II-29

Table 2: World Recent Past, Current & Future Analysis for Drug Discovery Technologies by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-29
Table 3: World 10-Year Perspective for Drug Discovery Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2001, 2006 & 2010 (includes corresponding Graph/Chart) II-29Analytics by Drug Discovery Technology Type II-30
Table 4: World Recent Past, Current & Future Analysis for Bioanalytical Instruments by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-30
Table 5: World 10-Year Perspective for Bioanalytical Instruments by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2001, 2006 & 2010 (includes corresponding Graph/Chart) II-30
Table 6: World Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-31
Table 7: World 10-Year Perspective for High Throughput Screening (HTS) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2001, 2006 & 2010 (includes corresponding Graph/Chart) II-31
Table 8: World Recent Past, Current & Future Analysis for Biochip by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-32
Table 9: World 10-Year Perspective for Biochip by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2001, 2006 & 2010 (includes corresponding Graph/Chart) II-32
Table 10: World Recent Past, Current & Future Analysis for Proteomics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-33
Table 11: World 10-Year Perspective for Proteomics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2001, 2006 & 2010 (includes corresponding Graph/Chart) II-33
Table 12: World Recent Past, Current & Future Analysis for Genomics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-34
Table 13: World 10-Year Perspective for Genomics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2001, 2006 & 2010 (includes corresponding Graph/Chart) II-34
Table 14: World Recent Past, Current & Future Analysis for Bioinformatics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-35
Table 15: World 10-Year Perspective for Bioinformatics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2001, 2006 & 2010 (includes corresponding Graph/Chart) II-35
Table 16: World Recent Past, Current & Future Analysis for Pharmacogenomics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-36
Table 17: World 10-Year Perspective for Pharmacogenomics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2001, 2006 & 2010 (includes corresponding Graph/Chart) II-36
Table 18: World Recent Past, Current & Future Analysis for Other Drug Discovery Technologies by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-37
Table 19: World 10-Year Perspective for Other Drug Discovery Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2001, 2006 & 2010 (includes corresponding Graph/Chart) II-37

III. MARKET

1. The United States III-1

A. Market Analysis III-1
Current & Future Analysis III-1
Government Aids Proteomics Research III-1
Product Launches III-1
Strategic Corporate Developments III-4
Focus on Select US Players III-10
Abbott Laboratories III-10
Affymetrix Inc. III-10
Agilent Technologies Inc. III-10
Albany Molecular Research, Inc. III-10
Amersham Biosciences III-11
Applera Corporation III-11
ArQule Inc. III-11
BD Biosciences III-11
Bio-Rad Laboratories, Inc. III-11
Caliper Life Sciences, Inc. III-12
Capital GenomiX III-12
Charles River Laboratories International, Inc. III-12
ChemBridge Corporation III-12
deCODE Genetics, Inc. III-12
Discovery Partners International Inc. III-13
HistoRx, Inc. III-13
ICOS Corporation III-13
Incyte Corporation (Formerly Incyte Genomics Inc.) III-13
Invitrogen Corporation III-13
Medarex, Inc. III-13
Merck & Co., Inc. III-14
Millennium Pharmaceuticals, Inc. III-14
PerkinElmer, Inc. III-14
Pharmacopeia Drug Discovery, Inc. III-14
Provid Pharmaceuticals, Inc. III-14
Tigris Pharmaceuticals, Inc. III-14
Sigma-Aldrich III-15
Tripos, Inc. III-15
B. Market Analytics III-15
Table 20: US Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, HTS, Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-15
Table 21: US 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Dollar Sales for Bioanalytical Instruments, HTS, Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2001, 2006 & 2010 (includes corresponding Graph/Chart) III-16

2. Canada III-17

A. Market Analysis III-17
Current & Future Analysis III-17
Canada Focuses on Proteomics Research III-17
Caprion Pharmaceuticals Inc. - A Key Player III-17
B. Market Analytics III-18
Table 22: Canadian Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-18
Table 23: Canadian 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Dollar Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2001, 2006 & 2010 (includes corresponding Graph/Chart) III-19

3. Japan III-20

A. Market Analysis III-20
Current & Future Analysis III-20
Japan Resembles US in Life Science Research III-20
Focus on Select Japanese Players III-20
BioSciences Group III-20
Shimadzu Corporation III-20
B. Market Analytics III-21
Table 24: Japanese Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-21
Table 25: Japanese 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Dollar Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2001, 2006 & 2010 (includes corresponding Graph/Chart) III-22

4. Europe III-23

A. Market Analysis III-23
Current & Future Analysis III-23
Market Trends III-23
European Market for Drug Discovery Tools III-23
UK Government Supports Proteomics Research III-24
Drug Discovery Outsourcing in Europe III-24
Recent Industry Activity III-24
Focus on Select European Players III-25
AstraZeneca (UK) III-25
deCODE Genetics, Inc (Iceland) III-26
Evotec AG (Germany) III-26
Inpharmatica (UK) III-26
NascaCell IP GmbH (Germany) III-26
Quantum Pharmaceuticals (Russia) III-26
Tecan Group (Switzerland) III-26
UCB (Belgium) III-27
B. Market Analytics III-27
Table 26: European Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-27
Table 27: European 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Dollar Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2001, 2006 & 2010 (includes corresponding Graph/Chart) III-28

5. Rest of World III-29

A. Market Analysis III-29
Current & Future Analysis III-29
Market Trends III-29
Asia-Pacific - Emerging Opportunities III-29
Cost Advantage in Asia Attracts Global Drug Discovery Industry III-29
Regulations Affect Asia-Pacific Drug Discovery Market III-29
PerkinElmer Opens New Technology Center in Shanghai III-30
Focus on Select Players III-30
National Center for Drug Screening (China) III-30
Proteome Systems (Australia) III-30
B. Market Analytics III-31
Table 28: Rest of World Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-31
Table 29: Rest of World 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Dollar Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2001, 2006 & 2010 (includes corresponding Graph/Chart) III-32

IV. COMPETITION

1. 3DM, Inc. (USA) IV-1
2. Abbott Laboratories (USA) IV-2
Table 30: First Quarter Sales Analysis: 2005-2006 (In US$ billion) IV-4
Table 31: Annual Sales Analysis: 2004-2005 (In US$ billion) IV-4
3. ACADIA Pharmaceuticals, Inc. (USA) IV-11
Table 32: First Quarter Sales Analysis: 2005-2006(In US$ million) IV-12
Table 33: Annual Sales Analysis: 2004-2005 (In US$ million) IV-12
Table 34: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-12
4. Advion Biosciences, Inc. (USA) IV-13
5. Affymax, Inc. (USA) IV-14
6. Affymetrix, Inc. (USA) IV-15
Table 35: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-16
Table 36: Annual Sales Analysis: 2004-2005 (In US$ million) IV-16
Perlegen Sciences, Inc. (USA) IV-20
Table 37: Annual Sales Analysis: 2003-2005 (In US$ million) IV-20
7. Agilent Technologies, Inc. (USA) IV-22
Table 38: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-24
Table 39: Annual Sales Analysis: 2004-2005 (In US$ million) IV-24
Table 40: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-24
Table 41: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-24
Table 42: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-25
8. Albany Molecular Research, Inc. (USA) IV-32
Table 43: Annual Sales Analysis: 2004-2005 (In US$ million) IV-32
9. Alnis Biosciences, Inc. (USA) IV-34
10. Alnylam Pharmaceuticals, Inc. (USA) IV-35
Table 44: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-35
Table 45: Annual Sales Analysis: 2004-2005 (In US$ million) IV-35
Table 46: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-36
11. Anadys Pharmaceuticals (USA) IV-37
Table 47: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-38
Table 48: Annual Sales Analysis: 2004-2005 (In US$ million) IV-38
Table 49: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-38
12. Analytik Jena AG (Germany) IV-39
13. ANP Technologies, Inc. (USA) IV-40
14. Apath LLC (USA) IV-41
15. Applera Corporation (USA) IV-43
Table 50: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ million) IV-44
Table 51: Nine Months Sales Analysis by Segment: 2005-2006 (Nine Months Ended, March) (In US$ million) IV-44
Table 52: Annual Sales Analysis: 2004-2005 (In US$ million) IV-44
Table 53: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-44
Applied Biosystems (USA) IV-47
Table 54: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ billion) IV-48
Table 55: Nine Months Sales Analysis by Quarter: 2005-2006 (Nine Months Ended, March) (In US$ billion) IV-48
Table 56: Nine Months Sales Analysis by Segment:2005-2006 (Nine Months Ended, March) (In US$ billion) IV-48
Table 57: Nine Months Sales Analysis by Product: 2005-2006 (Nine Months Ended, March) (In US$ billion) IV-48
Table 58: Nine Months Sales Analysis by Geographic Region: 2005-2006 (Nine Months Ended, March) (In US$ billion) IV-48
Table 59: Annual Sales Analysis: 2004-2005 (In US$ billion) IV-49
Celera Genomics Group (USA) IV-52
Table 60: Annual Sales Analysis: 2003-2005 (In US$ million) IV-53
16. Archemix Corporation (USA) IV-54
17. Arena Pharmaceuticals, Inc. (USA) IV-56
Table 61: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-56
Table 62: Annual Sales Analysis: 2004-2005 (In US$ million) IV-57
Table 63: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-57
18. Array BioPharma, Inc. (USA) IV-58
19. AstraZeneca PLC (UK) IV-60
Table 64: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-62
Table 65: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In US$ million) IV-62
Table 66: Annual Sales Analysis: 2004-2005 (In US$ million) IV-63
Table 67: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-63
20. Bioanalytical Systems, Inc. (USA) IV-69
Table 68: Half Yearly Sales Analysis: 2006-2005 (H1) (In US$ million) IV-69
Table 69: Annual Sales Analysis: 2004-2005 (In US$ million) IV-69
Table 70: Annual Sales Analysis by Quarter:2004-2005 (In US$ million) IV-70
Table 71: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-70
21. BD Biosciences (USA) IV-72
22. Beckman Coulter, Inc. (USA) IV-81
Table 72: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-85
Table 73: Annual Sales Analysis: 2004-2005(In US$ million) IV-85
Table 74: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-85
Table 75: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-85
23. Benitec Ltd. (Australia) IV-88
Benitec, Inc. (USA) IV-89
24. Berthod Technologies GmbH & Co. (Germany) IV-90
25. Biacore International AB (Sweden) IV-92
Table 76: First Quarter Sales Analysis: 2005-2006 (In SEK million) IV-92
Table 77: Annual Sales Analysis: 2004-2005 (In SEK million) IV-93
26. BioCrystal Limited (USA) IV-95
27. BioForce Nanosciences, Inc. (USA) IV-96
28. BioImagene, Inc. (USA) IV-98
29. Bio-Rad Laboratories, Inc. (USA) IV-101
Table 78: First Quarter Sales Analysis: 2005-2006(In US$ million) IV-102
Table 79: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million) IV-102
Table 80: Annual Sales Analysis: 2003-2005 (In US$ million) IV-103
Table 81: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-103
Table 82: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-103
Table 83: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-103
Table 84: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) IV-104
Table 85: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-104
30. Bioscan, Inc. (USA) IV-114
31. BioSciences Group (USA) IV-118
32. Biotech India (India) IV-119
33. Bio-Tek Instruments, Inc. (USA) IV-120
34. BioTrove, Inc. (USA) IV-123
35. Bristol-Myers Squibb Company (USA) IV-125
Table 86: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-126
Table 87: Annual Sales Analysis: 2003-2005 (In US$ million) IV-126
Table 88: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) IV-127
Table 89: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-127
36. Caliper Life Sciences, Inc. (USA) IV-130
Table 90: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-131
Table 91: Annual Sales Analysis: 2003-2005(In US$ million) IV-131
Table 92: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-131
Table 93: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-131
37. Cambridge Antibody Technology (UK) IV-134
38. Capital Genomix (USA) IV-136
39. CapitalBio Corporation (China) IV-137
40. Caprion Pharmaceuticals, Inc. (Canada) IV-138
41. Cellomics, Inc. (USA) IV-140
42. Cenix BioScience GmbH (Germany) IV-141
43. Cerep (France) IV-143
Table 94: First Quarter Sales Analysis: 2005-2006 (In € million) IV-144
Table 95: Annual Sales Analysis: 2003-2005 (In € million) IV-144
44. Cetek Corporation (USA) IV-144
45. CGI Pharmaceuticals, Inc. (USA) IV-145
46. Charles River Laboratories (USA) IV-147
Table 96: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-148
Table 97: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million) IV-149
Table 98: Annual Sales Analysis: 2003-2005 (In US$ million) IV-149
Table 99: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-149
Table 100: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-149
Table 101: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-150
Table 102: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) IV-150
Table 103: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-150
47. ChemBridge Corporation (USA) IV-151
48. ChemDiv, Inc. (USA) IV-152
49. Chugai Pharmaceutical Co., Ltd. (Japan) IV-154
Table 104: First Quarter Sales Analysis: 2005-2006 (In ¥ million) IV-155
Table 105: Annual Sales Analysis: 2003-2005 (In ¥ million) IV-155
50. CombiMatrix Corporation (USA) IV-158
51. Compugen USA, Inc. (USA) IV-160
52. CrystalPlex Corporation (USA) IV-161
53. Cytokinetics, Inc. (USA) IV-162
Table 106: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-162
54. CytRx Corporation (USA) IV-163
Table 107: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-163
Table 108: Annual Sales Analysis: 2004-2005 (In US$ million) IV-164
55. deCODE Genetics (Iceland) IV-165
Table 109: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-165
Table 110: Annual Sales Analysis: 2004-2005 (In US$ million) IV-166
Table 111: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-166
Table 112: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-166
56. Deltagen, Inc. (USA) IV-168
57. DevGen (Belgium) IV-169
58. Discovery Genomics, Inc. (DGI) (USA) IV-171
59. Discovery Partners International, Inc. (USA) IV-172
Table 113: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-173
Table 114: First Quarter Sales Analysis by Operation: 2005-2006 (In US$ million) IV-173
Table 115: Annual Sales Analysis: 2004-2005 (In US$ million) IV-173
Table 116: Annual Sales Analysis by Operation: 2004-2005 (In US$ million) IV-173
60. Eksigent Technologies LLC (USA) IV-176
61. Eli Lilly and Company (USA) IV-179
Table 117: Annual Sales Analysis: 2003-2005 (In US$ million) IV-180
62. Entelos, Inc. (USA) IV-187
63. Epigem Limited (UK) IV-190
64. EraGen Biosciences, Inc. (USA) IV-192
65. Evident Technologies (USA) IV-193
66. Evotec AG (Germany) IV-195
Table 118: First Quarter Sales Analysis: 2005-2006 (In € million) IV-195
Table 119: First Quarter Sales Analysis by Segment: 2005-2006 (In € million) IV-195
Table 120: Annual Sales Analysis: 2004-2005 (In € million) IV-196
Table 121: Annual Sales Analysis by Segment: 2004-2005 (In € million) IV-196
Table 122: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million): IV-196
67. Exelixis, Inc. (USA) IV-198
Table 123: Annual Sales Analysis: 2003-2005 In US$ million) IV-198
Table 124: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-199
68. Exonhit Therapeutics SA (France) IV-202
69. Fluorous Technologies, Inc. (USA) IV-204
70. Galapagos NV (Belgium) IV-205
71. GE Healthcare Lifesciences (USA) IV-207
72. Gene Logic, Inc. (USA) IV-208
Table 125: First Quarter Sales Analysis:
2005-2006 (In US$ million) IV-209
Table 126: Annual Sales Analysis: 2003-2005 (In US$ million) IV-209
Table 127: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-210
Table 128: Annual Sales Analysis by Division: 2004-2005 (In US$ million) IV-210
73. Gene Network Sciences (USA) IV-212
74. Genstruct (USA) IV-213
75. Genzyme Corporation (USA) IV-214
Table 129: First Quarter Sales Analysis: 2005-2006 (In US$ billion) IV-217
Table 130: Annual Sales Analysis: 2003-2005 (In US$ billion) IV-217
Table 131: Annual Sales Analysis by Quarter: 2004-2005 (In US$ billion) IV-217
Table 132: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion) IV-218
Table 133: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-218
Table 134: Annual Sales Analysis by Quarter: 2003-2004 (In US$ billion) IV-218
Table 135: Annual Sales Analysis by Segment: 2003-2004 (In US$ billion) IV-219
Table 136: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ billion) IV-219
76. GlaxoSmithKline (UK) IV-226
Table 137: Annual Sales Analysis: 2003-2005 (In £ million) IV-227
Table 138: Annual Sales Analysis by Segment: 2004-2005 (In £ million) IV-227
Table 139: Annual Sales Analysis by Segment:2003-2004 (In £ million) IV-227
77. GPC Biotech AG (Germany) IV-237
Table 140: First Quarter Sales Analysis: 2005-2006 (In € million) IV-238
Table 141: Annual Sales Analysis: 2004-2005 (In € million) IV-238
78. Graffinity Pharmaceutical Design GmbH (Germany) IV-239
79. Gyros AB (Sweden) IV-240
80. H. Lundbeck A/S (Denmark) IV-242
Table 142: Annual Sales Analysis: 2003-2005 (In DKK billion) IV-243
Table 143: Annual Sales Analysis by Quarter: 2004-2005 (In DKK billion) IV-244
Table 144: Annual Sales Analysis by Product: 2004-2005 (In DKK billion) IV-244
Table 145: Annual Sales Analysis by Geographic Region: 2004-2005 (In DKK billion) IV-244
Table 146: Annual Sales Analysis by Geographic Region: 2003-2004 (In DKK billion) IV-244
81. HistoRx, Inc. (USA) IV-249
82. Human Genome Sciences, Inc. (USA) IV-252
Table 147: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-253
Table 148: Annual Sales Analysis: 2003-2005 (In US$ million) IV-253
Table 149: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-253
83. Hybrigenics SA (France) IV-255
84. Icagen, Inc. (USA) IV-256
Table 150: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-256
Table 151: Annual Sales Analysis: 2004-2005 (In US$ million) IV-257
Table 152: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-257
Table 153: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-257
85. Iconix Pharmaceuticals (USA) IV-258
86. ICOS Corporation (USA) IV-261
Table 154: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-261
Table 155: Annual Sales Analysis: 2004-2005 (In US$ million) IV-261
Table 156: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-262
87. Immusol, Inc. (USA) IV-264
88. Incyte Corporation (USA) IV-265
89. Inpharmatica Ltd. (UK) IV-266
90. Invitrogen Corporation (USA) IV-268
Table 157: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-269
Table 158: Annual Sales Analysis: 2003-2005 (In US$ million) IV-269
Table 159: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-269
91. Karo Bio AB (Sweden) IV-275
92. KTEC (Kansas Technology Enterprise Corporation) (USA) IV-276
93. Lexicon Genetics, Inc. (USA) IV-277
Table 160: Annual Sales Analysis: 2004-2005 (In US$ million) IV-277
Table 161: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-278
94. Ligand Pharmaceuticals (USA) IV-280
Table 162: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-281
Table 163: Annual Sales Analysis: 2003-2005 (In US$ million) IV-281
95. Lion Bioscience AG (Germany) IV-281
96. Living Cell Technologies Ltd. (Australia) IV-282
97. Medarex, Inc. (USA) IV-283
Table 164: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-284
Table 165: Annual Sales Analysis: 2003-2005 (In US$ million) IV-284
Table 166: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-284
98. Memorec Stoffel GmbH (Germany) IV-288
99. Merck & Co., Inc. (USA) IV-290
Table 167: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-291
Table 168: First Quarter Sales Analysis by Product: 2005-2006 (In US$ million) IV-291
Table 169: Annual Sales Analysis: 2003-2005 (In US$ million) IV-291
Table 170: Annual Sales Analysis by Product: 2004-2005 (In US$ million) IV-292
Table 171: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-292
Table 172: Annual Sales Analysis by Product: 2003-2004 (In US$ million) IV-292
Table 173: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-293
Rosetta Inpharmatics LLC (USA) IV-297
100. Millennium Pharmaceuticals Limited (UK) IV-298
101. Molecular Devices Corporation (USA) IV-299
Table 174: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-300
Table 175: Annual Sales Analysis: 2003-2005 (In US$ million) IV-300
Table 176: Annual Sales Analysis by Product: 2004-2005 (In US$ million) IV-300
Table 177: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-300
Table 178: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-300
102. Multicell Technologies, Inc. (USA) IV-304
103. Nanostream, Inc. (USA) IV-305
104. National Center for Drug Screening (China) IV-305
105. Neurogen Corporation (USA) IV-306
Table 179: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-307
Table 180: Annual Sales Analysis: 2003-2005 (In US$ million) IV-307
Table 181: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-307
Table 182: Annual Sales Analysis by Quarter: 2003-2004 (In US$ million) IV-308
106. Novartis Institutes For Biomedical Research (NIBR) (USA) IV-308
107. Oncoimmunin, Inc. (USA) IV-309
108. Origene Technologies, Inc. (USA) IV-311
109. Palatin Technologies, Inc. (USA) IV-312
110. Pall Corporation (USA) IV-313
Table 183: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, April) (In US$ million) IV-315
Table 184: Nine Months Sales Analysis by Segment: 2005-2006 (Nine Months Ended, April) (In US$ million) IV-315
Table 185: Nine Months Sales Analysis by Geographic Region: 2005-2006 (Nine Months Ended, April) (In US$ million) IV-31
Table 186: Annual Sales Analysis: 2004-2005 (In US$ million) IV-316
Table 187: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-316
Table 188: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-316
111. PerkinElmer, Inc. (USA) IV-320
Table 189: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-322
Table 190: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million) IV-322
Table 191: Annual Sales Analysis: 2003-2005 (In US$ million) IV-322
Table 192: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-322
Table 193: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-323
Table 194: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-323
Table 195: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) IV-323
Table 196: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-323
112. Pharmacopeia, Inc. (USA) IV-334
Accelrys, Inc. (USA) IV-336
113. PharmaSeq, Inc. (USA) IV-342
114. Physiomics PLC (UK) IV-343
115. Promega Corporation (USA) IV-344
116. Proteome Systems Limited (Australia) IV-355
117. Protiveris, Inc. (USA) IV-356
118. Provid Pharmaceuticals, Inc. (USA) IV-357
119. Qiagen NV (The Netherlands) IV-358
Table 197: Annual Sales Analysis: 2003-2005 (In US$ million) IV-358
Table 198: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-359
120. Quantum Pharmaceuticals (Russia) IV-362
121. Rigel Pharmaceuticals, Inc. (USA) IV-363
Table 199: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-363
Table 200: Annual Sales Analysis: 2003-2005 (In US$ million) IV-364
Table 201: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-364
122. SGX Pharmaceuticals, Inc. (USA) IV-365
Table 202: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-365
Table 203: Annual Sales Analysis: 2003-2005 (In US$ million) IV-366
Table 204: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-366
123. Shimadzu Corporation (Japan) IV-368
Table 205: Annual Sales Analysis: 2003-2005 (In ¥ million) IV-369
Table 206: Annual Sales Analysis by Segment: 2004-2005 (In ¥ million) IV-370
Table 207: Annual Sales Analysis by Geographic Region: 2004-2005 (In ¥ million) IV-370
Table 208: Annual Sales Analysis by Segment: 2003-2004 (In ¥ million) IV-370
Table 209: Annual Sales Analysis by Geographic Region: 2003-2004 (In ¥ million) IV-370
124. Sigma-Aldrich Corporation (USA) IV-378
Table 210: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-379
Table 211: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million) IV-379
Table 212: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In US$ million) IV-379
Table 213: Annual Sales Analysis: 2003-2005 (In US$ million) IV-379
Table 214: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-380
Table 215: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-380
Table 216: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-380
Table 217: Annual Sales Analysis by Quarter: 2003-2004 (In US$ million) IV-380
Table 218: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) IV-381
Table 219: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-381
125. Takeda Pharmaceutical Company Limited (Japan) IV-389
Table 220: Annual Sales Analysis: 2003-2004 (In ¥ million) IV-390
Table 221: Annual Sales Analysis by Segment: 2003-2004 (In ¥ million) IV-390
Table 222: Annual Sales Analysis by Geographic Region: 2003-2004 (In ¥ million) IV-390
126. Tandem Labs (USA) IV-395
127. Tecan Group AG (Switzerland) IV-396
128. Tripos, Inc. (USA) IV-397
Table 223: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-398
Table 224: First Quarter Sales Analysis by Product: 2005-2006 (In US$ million) IV-398
Table 225: Annual Sales Analysis: 2003-2005 In US$ million) IV-398
Table 226: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-398
Table 227: Annual Sales Analysis by Product: 2004-2005 (In US$ million) IV-399
Table 228: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-399
129. UCB SA (Belgium) IV-401
Table 229: Annual Sales Analysis: 2004-2005 (In € million) IV-402
Table 230: Annual Sales Analysis by Product: 2004-2005 (In € million) IV-403
Table 231: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million) IV-403
130. Vertex Pharmaceuticals, Inc. (USA) IV-407
Table 232: First Quarter Sales Analysis: 2006-2005 (In US$ million) IV-408
Table 233: Annual Sales Analysis: 2003-2005 (In US$ million) IV-408
Table 234: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-408
131. Virogenomics, Inc. (USA) IV-410
132. Xcellerex, Inc. (USA) IV-411
133. Xenon Pharmaceuticals, Inc. (USA) IV-411
134. Zyomyx, Inc. (USA) IV-412

Drug Discovery Technologies

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. Industry Overview II-1

2. Market Trends II-4

3. Drug Discovery - An Overview II-6

4. Product Launches II-11

5. Recent Industry Activity II-14

6. Focus on Select Global Players II-22

7. Global Market Perspective II-29

III. MARKET

1. The United States III-1

2. Canada III-17

3. Japan III-20

4. Europe III-23

5. Rest of World III-29

IV. COMPETITION